Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing
Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in the European Union and other jurisdictions. In Spain, the 100% academic anti-CD19 CART-cell product varnimcabtage...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1005457/full |
| _version_ | 1828170252067799040 |
|---|---|
| author | Nuria Martinez-Cibrian Nuria Martinez-Cibrian Marta Español-Rego Mariona Pascal Mariona Pascal Julio Delgado Julio Delgado Julio Delgado Valentín Ortiz-Maldonado Valentín Ortiz-Maldonado |
| author_facet | Nuria Martinez-Cibrian Nuria Martinez-Cibrian Marta Español-Rego Mariona Pascal Mariona Pascal Julio Delgado Julio Delgado Julio Delgado Valentín Ortiz-Maldonado Valentín Ortiz-Maldonado |
| author_sort | Nuria Martinez-Cibrian |
| collection | DOAJ |
| description | Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in the European Union and other jurisdictions. In Spain, the 100% academic anti-CD19 CART-cell product varnimcabtagene autoleucel (var-cel, ARI-0001 cells) has been extraordinarily approved under the Hospital Exemption clause for the treatment of patients older than 25 years of age with R/R acute lymphoblastic leukaemia. Var-cel has also been granted PRIority MEdicines designation by the European Medicines Agency for the same indication. In this review we reveal some practical aspects related to the preparation and administration of academic point-of-care CART-cell products, using var-cel as an example, and put them into the context of commercial products. |
| first_indexed | 2024-04-12T03:05:49Z |
| format | Article |
| id | doaj.art-1b4381fb80f14eb9b8ac5d72d310c398 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T03:05:49Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1b4381fb80f14eb9b8ac5d72d310c3982022-12-22T03:50:29ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.10054571005457Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturingNuria Martinez-Cibrian0Nuria Martinez-Cibrian1Marta Español-Rego2Mariona Pascal3Mariona Pascal4Julio Delgado5Julio Delgado6Julio Delgado7Valentín Ortiz-Maldonado8Valentín Ortiz-Maldonado9Department of Haematology, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, SpainDepartment of Immunology, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, SpainDepartment of Immunology, Hospital Clínic de Barcelona, Barcelona, SpainDepartment of Haematology, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, SpainDepartment of Medicine, Universitat de Barcelona, Barcelona, SpainDepartment of Haematology, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, SpainChimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in the European Union and other jurisdictions. In Spain, the 100% academic anti-CD19 CART-cell product varnimcabtagene autoleucel (var-cel, ARI-0001 cells) has been extraordinarily approved under the Hospital Exemption clause for the treatment of patients older than 25 years of age with R/R acute lymphoblastic leukaemia. Var-cel has also been granted PRIority MEdicines designation by the European Medicines Agency for the same indication. In this review we reveal some practical aspects related to the preparation and administration of academic point-of-care CART-cell products, using var-cel as an example, and put them into the context of commercial products.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1005457/fullchimeric antigen receptor (CAR)cluster of differentiation 19 (CD19)point-of-careB-cellNon-Hodgkin's lymphoma (NHL)Acute lymphoblastic leukemia (ALL) |
| spellingShingle | Nuria Martinez-Cibrian Nuria Martinez-Cibrian Marta Español-Rego Mariona Pascal Mariona Pascal Julio Delgado Julio Delgado Julio Delgado Valentín Ortiz-Maldonado Valentín Ortiz-Maldonado Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing Frontiers in Immunology chimeric antigen receptor (CAR) cluster of differentiation 19 (CD19) point-of-care B-cell Non-Hodgkin's lymphoma (NHL) Acute lymphoblastic leukemia (ALL) |
| title | Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing |
| title_full | Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing |
| title_fullStr | Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing |
| title_full_unstemmed | Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing |
| title_short | Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing |
| title_sort | practical aspects of chimeric antigen receptor t cell administration from commercial to point of care manufacturing |
| topic | chimeric antigen receptor (CAR) cluster of differentiation 19 (CD19) point-of-care B-cell Non-Hodgkin's lymphoma (NHL) Acute lymphoblastic leukemia (ALL) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1005457/full |
| work_keys_str_mv | AT nuriamartinezcibrian practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT nuriamartinezcibrian practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT martaespanolrego practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT marionapascal practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT marionapascal practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT juliodelgado practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT juliodelgado practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT juliodelgado practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT valentinortizmaldonado practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing AT valentinortizmaldonado practicalaspectsofchimericantigenreceptortcelladministrationfromcommercialtopointofcaremanufacturing |